Ciprofloxacin 500 mgr.
Active ingredient and composition:
Each film coated tablet contains:
Ciprofloxacin Hydrochloride BP equivalent to Ciprofloxacin 500 mg.
Excipients: micro crystalline cellulose powder, povidone, magnesium stearate, colloidal anhydrous silica, polacrilin potassium, sodium alginate, titanium dioxide.
Lower respiratory tract infections due to Gram-negative bacteria, exacerbations of chronic obstructive pulmonary disease, broncho-pulmonary infections in cystic fibrosis or in bronchiectasis, pneumonia, chronic suppurative otitis media, acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria.
Hypersensitivity to the active substance, to other quinolones or to any of the excipients. Concomitant administration of Ciprofloxacin and Tizanidine. Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections, Ciprofloxacin must be co-administered with other appropriate antibacterial agents. Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.
A white coloured, elongated shaped tablet with score on one side and plain on another side. 10 such tablets packed in blister pack and 10 such blisters are packed in a carton (100 tablets). Possibility to adapt packing and quantities to customer needs.
For oral administration.